Industry
Alessio Fasano, Chair of the Congress, shares an overview of the event and the future challenges.
Industry
Sponsored by
The Research and Development laboratories of Biofarma Group have developed a formulation that can represent a valid aid in case of vaginal dysbiosis and associated disorders.
Key areas of interest include circadian rhythms, neurological conditions, metabolic disorders, and oncology.
During IPC 2024, George Paraskevakos shared recent updates on market developments and an overview of the Biotic-related survey.
VOWST is the first and only orally administered microbiota-based therapeutic approved by the U.S. FDA for the prevention of recurrent Clostridioides difficile infection in adults.
The report summarizes numerous presentations on the skin microbiome, covering topics such as acne, anti-aging, atopic dermatitis, and "microbiome-friendly" cosmetics.
The product, based on the pioneering research of Dr. Jacques Ravel, is the first of its kind to be clinically validated for establishing an optimal vaginal microbiome, dominated by Lactobacillus…
Industry
Sponsored by
The company was honored with the Ingredient of the Year award in the Microbiome Modulation and the Beauty from Within category.
Bi104 is a microbiome-modifying biologic designed to diversify and modulate the gut microflora and metabolite profile.
AB-Biotics recently appointed to the IPA board of directors. What opportunities and future developments? We discussed this with Miquel Bonachera.
